Liver Diseases  >>  Isentress (raltegravir)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT01241773: TMC435-TiDP16-C123 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents Efavirenz and Raltegravir

Completed
1
48
Europe
raltegravir, TMC435 + raltegravir, TMC435, TMC435 + efavirenz, efavirenz
Tibotec Pharmaceuticals, Ireland
Hepatitis C Virus
04/11
04/11
NCT01253551: VX-950HEP1001 - Drug-drug Interaction Study Between Telaprevir and Raltegravir

Completed
1
21
US, RoW
Treatment sequence AB, Treatment sequence BA
Tibotec BVBA, Vertex Pharmaceuticals Incorporated
Hepatitis C
 
04/11
LIVERAL, NCT01289951: Pharmacokinetic Study of Raltegravir in Human Immunodeficiency Virus/Hepatitis C Virus (HIV/VHC) Coinfected Patients With Advanced (Child-Pugh C) Hepatic Cirrhosis

Completed
1
10
Europe
Raltegravir 400 mg/12hours
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal, Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Hepatitis C
06/11
10/11
NCT01525628: Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

Completed
1
72
US, Canada, Europe
midazolam, BI 201335, tenofovir, caffeine, tolbutamide, pegylated interferon, BI 207127, ribavirin
Boehringer Ingelheim
Hepatitis C, Chronic
12/13
10/14

Download Options